Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases

European Journal of Endocrinology

Volumn 160, Issue 4, 2009, Pages 619-624

  Verburg, Frederick A ^a   Mäder, Uwe ^a   Luster, Markus ^a   Reiners, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SURVIVAL TIME; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME; AGING; FACTUAL DATABASE; GERMANY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PAPILLARY CARCINOMA; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; SURVIVAL; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; CHILD; DATABASES, FACTUAL; FEMALE; GERMANY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 64549089687     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0805     Document Type: Article

References (28)

1. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 1994 97 418-428.
2. Chow SM, Law SC, Au SK, Leung TW, Chan PT, Mendenhall WM & Lau WH. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head & Neck 2002 24 670-677.
3. Hermanek P, Hutter RVP, Sobin LM, Wagner G & Wittekind C. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. edn 5 New York, Berlin, Heidelberg: Springer, 1997.
4. Sobin LH & Wittekind C. Classification of Malignant Tumors. edn 6 New York: Wiley-Liss, 2002.
5. Cady B & Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988 104 947-953.
6. Shaha AR, Loree TR & Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 1994 116 1036-1040.
7. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T & Maxon HR III. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998 83 1012-1021.
8. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK & Holzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000 89 202-217.
9. Hölzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK & Hundahl SA. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. US and German Thyroid Cancer Group. Cancer 2000 89 192-201.
10. Machens A, Holzhusen HJ & Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysis. Cancer 2005 103 2269-2273.
11. LH Sobin & C Wittekind (eds), TNM classification of malignant Tumors, edn 6, New York: Wiley-Liss, 2002.
12. LH Sobin & C Wittekind (eds), TNM classification of malignant Tumours, edn 5, Berlin, Heidelburg, New York, Tokyo: Springer, 1997.
13. Gulcelik MA, Gulcelik NE, Kuru B, Camlibel M & Alagol H. Prognostic factors determining survival in differentiated thyroid cancer. Journal of Surgical Oncology 2007 96 598-604.
14. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M & Bartenstein P. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003 13 949-958.
15. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA & Smit JW. Survival and death causes in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 313-319.
16. DeGroot LJ, Kaplan EL, Shukla MS, Salti G & Straus FH. Morbidity and mortality in follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1995 80 2946-2953.
17. Lundgren CI, Hall P, Dickman PW & Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma. Cancer 2005 106 524-531.
18. Haq M & Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clinical Endocrinology 2005 63 87-93.
19. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, RicardM, Lumbroso JD, De Vathaire F & SchlumbergerM. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2892-2899.
20. D'AvanzoA, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY & Clark OH. Follicular thyroid carcinoma: histology and prognosis. Cancer 2003 100 1123-1129.
21. Gharib H & Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Annals of Internal Medicine 1993 118 282-289.
22. Ravetto C, Colombo L & Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer 2000 90 357-363.
23. Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 2008 93 1600-1608.
24. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D & Westra WH. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clinical Cancer Research 2004 10 2761-2765.
25. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F & Santoro M. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2004 89 5175-5180.
26. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT & Fahey TJ III. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. Journal of Molecular Diagnostics 2006 8 490-498.
27. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & WiersingaW. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
28. Baudin E, Travagli JP,Ropers J, Mancusi F, Bruno-Bosio G, Caillou B, Cailleux AF, Lumbroso J, Parmentier C & Schlumberger M. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998 83 553-559.